Physician profile
Michael S Mihara
NPI 1750324919
$8,354.00
in general payments reported to CMS, 2019-2025
28 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,873 · 2020: $578 · 2021: $897 · 2022: $1,581 · 2023: $1,432 · 2024: $971 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,424.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,251.89 | 2019-2025 | Evenity, Prolia, Repatha |
| Amarin Pharma, INC. | $919.35 | 2019-2023 | |
| Lilly USA, LLC | $877.70 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $839.52 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $720.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $675.05 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $556.48 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $420.41 | 2021-2025 | |
| Pfizer INC. | $405.22 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $235.64 | 2019-2025 | Gardasil 9, M-M-R II, Capvaxive |
| Kowa Pharmaceuticals America, INC. | $180.03 | 2019-2023 | Livalo, Seglentis |
| Abbvie INC. | $179.14 | 2021-2025 | |
| Horizon Therapeutics Plc | $149.36 | 2019-2023 | Krystexxa, Tepezza |
| Teva Pharmaceuticals USA, INC. | $138.07 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $105.85 | 2022-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $94.60 | 2019-2020 | |
| Dexcom, INC. | $92.15 | 2020-2024 | Dexcom G6 Transmitter |
| Smith+Nephew, INC. | $78.53 | 2019 | |
| Arbor Pharmaceuticals, INC. | $73.99 | 2019 | |
| Abbott Laboratories | $72.82 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $66.69 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $55.95 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $36.99 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $35.72 | 2019 | |
| Inspire Medical Systems, INC. | $34.95 | 2023-2025 | Inspire |
| Janssen Pharmaceuticals, INC | $23.36 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $20.29 | 2021 | |
| Allergan, INC. | $13.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mihara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.